Females in Psychedelic Research: A Perspective for Advancing Research and Practice.

Ovarian hormone fluctuations, particularly estradiol and progesterone, modulate neurotransmitter systems involved in psychedelic pharmacology, including serotonin, dopamine, GABA, and glutamate. These hormonal changes across the menstrual cycle influence 5-HT2A receptor expression and functional connectivity, potentially affecting both the subjective intensity and therapeutic efficacy of psychedelics. The paper argues that incorporating menstrual phase tracking and hormonal assays into clinical trials and observational studies can reduce data variability, support individualized care, and improve informed consent practices for women. A better understanding of the interplay between female-specific biology and psychedelic pharmacodynamics is needed to advance safe, ethical, and effective therapies.

Study at a glance

Abstract

The influence of ovarian hormone fluctuations on neurochemistry, cognition, and psychological responses remains insufficiently examined in current psychedelic research and clinical protocols. Traditional practices and case studies underscore the importance of accounting for these factors in investigations of psychedelic effects. This opinion paper explores the critical intersections between female hormones and psychedelic experiences, informing improved research and practice. Estradiol (E2) and progesterone (P4), the primary ovarian hormones, modulate neurotransmitter systems central to psychedelic pharmacology, including serotonin (5-HT), dopamine, GABA, and glutamate. These hormonal interactions affect interhemispheric communication, synaptic plasticity, mood, cognition, and behavior. Fluctuations across the menstrual cycle influence 5-HT2A receptor expression and functional connectivity, potentially modulating both the subjective intensity and therapeutic efficacy of psychedelics. Additionally, oscillations in female hormones across the menstrual and life cycles affect mindset, a significant factor in safe and effective psychedelic use. These findings suggest that female hormonal variability may play a pivotal role in psychedelic experiences. Incorporating menstrual phase tracking and hormonal assays in both clinical trials and observational studies can reduce data variability, support individualized care, and improve informed consent practices. This would improve data integrity and ensure that women are fully informed about the potential influence of their hormonal state on their psychedelic experience, supporting truly informed consent. This paper emphasizes the need for an improved understanding of the complex interplay between female-specific biology and psychedelic pharmacodynamics to advance safe, ethical, and effective psychedelic research and therapies for women.